-- ============================================================================
-- SURGERY 3 MCQ BATCH 6: Benign Prostatic Hyperplasia (Questions 301-360)
-- Topic: Benign Prostatic Hyperplasia
-- ============================================================================

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES

-- Anatomy and Pathophysiology (1-15)
('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'The prostate gland is located:',
'Above the bladder', 'Below the bladder, surrounding the prostatic urethra', 'Lateral to the bladder', 'In the scrotum', 'In the perineum only',
'B', 'The prostate gland is located below the bladder, surrounding the prostatic urethra. It lies anterior to the rectum, allowing digital rectal examination. Reference: Campbell-Walsh Urology, 12th ed. 2020.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'The zones of the prostate include all EXCEPT:',
'Peripheral zone', 'Transition zone', 'Central zone', 'Anterior zone', 'Periurethral zone',
'D', 'The prostate has four zones: Peripheral zone (70%, most cancers), Transition zone (5-10%, where BPH develops), Central zone (25%), and Periurethral zone. There is no "anterior zone" - there is anterior fibromuscular stroma. Reference: McNeal JE. Am J Surg Pathol. 1988.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Benign prostatic hyperplasia primarily develops in the:',
'Peripheral zone', 'Transition zone', 'Central zone', 'Anterior fibromuscular stroma', 'Seminal vesicles',
'B', 'BPH develops in the transition zone and periurethral glands. This is why it causes urinary symptoms - the transition zone surrounds the prostatic urethra. In contrast, prostate cancer typically arises in the peripheral zone. Reference: Berry SJ. J Urol. 1984.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'The prevalence of histological BPH in men aged 60 years is approximately:',
'20%', '50%', '70%', '90%', '10%',
'B', 'Histological BPH is present in about 50% of men by age 60 and 90% by age 85. However, only about half of those with histological BPH develop significant symptoms. Reference: Berry SJ. J Urol. 1984.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'The two essential factors for BPH development are:',
'Smoking and alcohol', 'Aging and functioning testes (androgens)', 'Obesity and diabetes', 'Infection and inflammation', 'Diet and exercise',
'B', 'Two factors are essential for BPH: 1) Aging, and 2) Functioning testes (testosterone/DHT). Men castrated before puberty do not develop BPH. DHT is the primary androgen involved in prostate growth. Reference: Wilson JD. Endocr Rev. 1980.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Dihydrotestosterone (DHT) is converted from testosterone by:',
'Aromatase', '5-alpha reductase', 'Phosphodiesterase', 'Cyclooxygenase', 'Monoamine oxidase',
'B', '5-alpha reductase converts testosterone to dihydrotestosterone (DHT), which is the primary androgen stimulating prostate growth. There are two isoforms (Type 1 and Type 2). Type 2 predominates in the prostate. Reference: Wilson JD. Endocr Rev. 1980.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'The components of bladder outlet obstruction (BOO) include:',
'Static component only', 'Dynamic component only', 'Both static (tissue) and dynamic (smooth muscle tone) components', 'Neither component', 'Neural component only',
'C', 'BOO in BPH has two components: 1) Static component - physical obstruction by enlarged tissue, and 2) Dynamic component - smooth muscle tone in prostate/bladder neck mediated by alpha-1 adrenergic receptors. Reference: Lepor H. Urology. 1995.',
'medium', 'comprehension'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Alpha-1 adrenergic receptors in the prostate are predominantly:',
'Alpha-1A subtype', 'Alpha-1B subtype', 'Alpha-1D subtype', 'Beta-2 subtype', 'Muscarinic subtype',
'A', 'Alpha-1A receptors predominate in the prostate (70%) and are the target of selective alpha-blockers like tamsulosin. Alpha-1D receptors are found in the detrusor and may contribute to storage symptoms. Reference: Lepor H. Urology. 1995.',
'hard', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Secondary bladder changes in chronic BOO include:',
'Detrusor atrophy only', 'Detrusor hypertrophy, trabeculation, and eventually decompensation', 'No changes occur', 'Bladder cancer', 'Decreased bladder capacity only',
'B', 'Chronic BOO causes detrusor hypertrophy (to overcome obstruction), trabeculation, cellule and diverticula formation, and eventually detrusor decompensation with overflow incontinence and upper tract damage. Reference: Tubaro A. Eur Urol. 2003.',
'medium', 'comprehension'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Lower urinary tract symptoms (LUTS) are classified into:',
'Storage symptoms only', 'Voiding symptoms only', 'Storage, voiding, and post-micturition symptoms', 'Obstructive symptoms only', 'Irritative symptoms only',
'C', 'LUTS are classified into: 1) Storage (frequency, urgency, nocturia, incontinence), 2) Voiding (hesitancy, weak stream, intermittency, straining, prolonged voiding), and 3) Post-micturition (incomplete emptying, post-void dribble). Reference: Abrams P. Neurourol Urodyn. 2002.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Hesitancy in BPH is characterized by:',
'Difficulty holding urine', 'Difficulty initiating urination', 'Blood in urine', 'Pain during urination', 'Frequent urination',
'B', 'Hesitancy is difficulty initiating the urinary stream - the patient has to wait for urine flow to begin despite the urge to void. It is a voiding/obstructive symptom typical of BPH. Reference: Abrams P. Neurourol Urodyn. 2002.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Nocturia is defined as:',
'Daytime urinary frequency', 'Waking at night to urinate', 'Inability to hold urine', 'Pain at night', 'Blood in urine at night',
'B', 'Nocturia is waking from sleep to urinate. It significantly affects quality of life and sleep. In BPH, it results from incomplete bladder emptying and detrusor overactivity. Reference: Abrams P. Neurourol Urodyn. 2002.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'The International Prostate Symptom Score (IPSS) assesses:',
'Only voiding symptoms', 'Seven symptom questions plus quality of life', 'Only storage symptoms', 'Erectile function', 'Prostate size',
'B', 'IPSS consists of 7 questions about urinary symptoms (scored 0-5 each, max 35) plus 1 quality of life question. Scores: 0-7 mild, 8-19 moderate, 20-35 severe. It is the standard tool for assessing LUTS severity. Reference: Barry MJ. J Urol. 1992.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Acute urinary retention (AUR) is a complication of BPH defined as:',
'Frequent urination', 'Painful inability to void with bladder distension requiring catheterization', 'Leaking of urine', 'Blood in urine', 'Urinary tract infection',
'B', 'Acute urinary retention is the sudden inability to void despite a full bladder, requiring catheterization. It is painful, distressing, and a definite indication for BPH treatment. Risk factors include large prostate and high symptom scores. Reference: Emberton M. BJU Int. 2006.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Chronic urinary retention differs from acute urinary retention in that:',
'It is more painful', 'It develops gradually and may be painless with large residual volumes', 'It never causes complications', 'It always requires surgery', 'It only affects young men',
'B', 'Chronic urinary retention develops gradually, is usually painless, and involves large post-void residual volumes (often >1000mL). It can lead to overflow incontinence and upper tract damage (hydronephrosis, renal failure). Reference: Emberton M. BJU Int. 2006.',
'medium', 'comprehension'),

-- Diagnosis (16-30)
('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Digital rectal examination (DRE) in BPH typically reveals:',
'Irregular, hard nodules', 'Smooth, firm, symmetric enlargement', 'Boggy, tender prostate', 'Normal-sized prostate always', 'Cannot assess prostate',
'B', 'In BPH, DRE reveals a smooth, firm, symmetrically enlarged prostate with a preserved median sulcus. The texture is rubbery. Nodules, asymmetry, or induration suggest possible malignancy. Reference: Campbell-Walsh Urology. 2020.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'The median sulcus on DRE:',
'Is obliterated in all BPH', 'Is typically preserved in BPH unless grossly enlarged', 'Is only felt in prostate cancer', 'Is the site of all prostatic nodules', 'Cannot be felt on DRE',
'B', 'The median sulcus (groove between the lateral lobes) is typically preserved in BPH unless the gland is grossly enlarged. Obliteration of the sulcus with nodularity suggests possible malignancy requiring further evaluation. Reference: Campbell-Walsh Urology. 2020.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'PSA (Prostate Specific Antigen) levels in BPH:',
'Are always normal', 'May be mildly elevated due to increased prostate tissue', 'Are always greater than 10 ng/mL', 'Are not affected by prostate size', 'Are lower than in young men',
'B', 'PSA may be elevated in BPH due to increased amount of prostate epithelium. Approximately 0.3 ng/mL increase per gram of BPH tissue. PSA density (PSA/prostate volume) helps differentiate BPH from cancer. Reference: Roehrborn CG. J Urol. 1999.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Uroflowmetry measures:',
'Bladder pressure', 'Urine flow rate', 'Prostate size', 'Kidney function', 'Urine composition',
'B', 'Uroflowmetry measures the rate of urine flow during voiding. Maximum flow rate (Qmax) <10 mL/s suggests obstruction. It is a non-invasive test used to objectively assess voiding function. Reference: Abrams P. BJU Int. 2002.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'A maximum urinary flow rate (Qmax) of less than 10 mL/s suggests:',
'Normal voiding', 'Bladder outlet obstruction', 'Overactive bladder', 'Urethral stricture only', 'Excellent bladder function',
'B', 'Qmax <10 mL/s is highly suggestive of bladder outlet obstruction. Qmax 10-15 mL/s is equivocal. Qmax >15 mL/s is usually normal. However, low flow can also result from detrusor weakness. Reference: Abrams P. BJU Int. 2002.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Post-void residual (PVR) urine measurement:',
'Is not useful in BPH assessment', 'Helps assess bladder emptying efficiency', 'Measures kidney function', 'Requires catheterization always', 'Is only done after surgery',
'B', 'PVR measures urine remaining in the bladder after voiding. It indicates bladder emptying efficiency. Elevated PVR (>100-200mL) suggests significant retention. Can be measured by ultrasound or catheterization. Reference: McVary KT. J Urol. 2011.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Transrectal ultrasound (TRUS) of the prostate is used to:',
'Diagnose BPH definitively', 'Measure prostate volume and guide biopsy', 'Treat BPH', 'Replace DRE', 'Measure flow rate',
'B', 'TRUS measures prostate volume accurately (important for treatment planning), identifies the transition zone, and guides prostate biopsy when cancer is suspected. Prostate volume >30-40mL may benefit from 5-alpha reductase inhibitors. Reference: Terris MK. J Urol. 1991.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Urodynamic studies are indicated in BPH when:',
'Always before any treatment', 'Diagnosis is uncertain, prior surgery, or neurological disease present', 'Only for surgical planning', 'Only in young men', 'Never indicated',
'B', 'Urodynamics differentiate obstruction from detrusor underactivity and diagnose detrusor overactivity. Indicated when: diagnosis uncertain, previous surgery, neurological disease, suspected detrusor weakness, or failed prior treatment. Reference: McVary KT. J Urol. 2011.',
'hard', 'application'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Pressure-flow studies are the gold standard for diagnosing:',
'Prostate cancer', 'Bladder outlet obstruction', 'Kidney stones', 'Urinary tract infection', 'Erectile dysfunction',
'B', 'Pressure-flow urodynamics is the gold standard for diagnosing BOO. It simultaneously measures intravesical pressure and flow rate. High pressure with low flow indicates obstruction; low pressure with low flow indicates detrusor weakness. Reference: Abrams P. BJU Int. 2002.',
'hard', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Cystoscopy in BPH:',
'Is mandatory before treatment', 'Is not routinely required but useful before surgery or with hematuria', 'Replaces DRE', 'Is the only way to diagnose BPH', 'Is contraindicated',
'B', 'Cystoscopy is not routinely required for BPH diagnosis but is useful: before surgery (to assess bladder and urethra), with hematuria (to exclude bladder pathology), with recurrent UTI, or suspected urethral stricture. Reference: McVary KT. J Urol. 2011.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Serum creatinine is measured in BPH to:',
'Diagnose BPH', 'Assess for renal impairment from chronic retention', 'Measure PSA', 'Evaluate testosterone levels', 'Check for infection',
'B', 'Serum creatinine assesses renal function. Chronic urinary retention from BPH can cause bilateral hydronephrosis and post-renal kidney injury (obstructive uropathy). Elevated creatinine may indicate need for urgent decompression. Reference: McVary KT. J Urol. 2011.',
'easy', 'comprehension'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Urinalysis is performed in BPH assessment to:',
'Diagnose prostate cancer', 'Exclude infection, hematuria, and glucosuria', 'Measure prostate size', 'Assess flow rate', 'Check PSA levels',
'B', 'Urinalysis is a basic investigation to exclude: UTI (which can cause LUTS), hematuria (may indicate other pathology), and glucosuria (diabetes can cause polyuria/nocturia). Reference: McVary KT. J Urol. 2011.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Upper tract imaging (ultrasound or CT) in BPH is indicated when:',
'Always as part of routine workup', 'Hematuria, renal impairment, history of stones, or high residual volumes', 'Never needed', 'Only after surgery', 'Only in young men',
'B', 'Upper tract imaging is not routine but indicated when: hematuria (to exclude tumor), elevated creatinine (hydronephrosis), history of urolithiasis, recurrent UTI, or very high post-void residual suggesting upper tract involvement. Reference: McVary KT. J Urol. 2011.',
'medium', 'application'),

-- Medical Treatment (31-45)
('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Watchful waiting in BPH is appropriate for:',
'All patients', 'Patients with mild symptoms (IPSS <8) who are not bothered', 'Patients with acute retention', 'Patients with renal failure', 'No patients',
'B', 'Watchful waiting (lifestyle advice, monitoring) is appropriate for patients with mild symptoms (IPSS <8) who are not significantly bothered. Includes fluid management, avoiding caffeine/alcohol, timed voiding, and review. Reference: McVary KT. J Urol. 2011.',
'easy', 'application'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Alpha-blockers treat BPH symptoms by:',
'Shrinking the prostate', 'Relaxing smooth muscle in prostate and bladder neck', 'Killing prostate cells', 'Blocking testosterone', 'Increasing urine production',
'B', 'Alpha-1 adrenergic blockers relax smooth muscle in the prostate, bladder neck, and prostatic capsule (dynamic component of obstruction). They provide rapid symptom relief (within days) but do not reduce prostate size. Reference: Lepor H. Urology. 1995.',
'easy', 'comprehension'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Examples of alpha-blockers used for BPH include:',
'Finasteride and dutasteride', 'Tamsulosin, alfuzosin, and silodosin', 'Oxybutynin and tolterodine', 'Tadalafil only', 'Doxazosin only (for hypertension)',
'B', 'Common alpha-blockers for BPH: tamsulosin (uroselective), alfuzosin, silodosin (highly selective), doxazosin, terazosin. The uroselective agents (tamsulosin, silodosin) have fewer cardiovascular side effects. Reference: Lepor H. J Urol. 2007.',
'easy', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Common side effects of alpha-blockers include:',
'Gynecomastia', 'Postural hypotension, dizziness, retrograde ejaculation', 'Prostate shrinkage', 'Hair growth', 'Weight gain',
'B', 'Alpha-blocker side effects include: postural hypotension (especially non-selective), dizziness, asthenia, and retrograde/anejaculation (especially tamsulosin). Intraoperative floppy iris syndrome (IFIS) can occur during cataract surgery. Reference: Lepor H. J Urol. 2007.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'5-alpha reductase inhibitors work by:',
'Relaxing smooth muscle', 'Blocking conversion of testosterone to DHT, reducing prostate volume', 'Increasing urine flow directly', 'Treating infection', 'Blocking alpha receptors',
'B', '5-alpha reductase inhibitors (finasteride, dutasteride) block conversion of testosterone to DHT, causing prostate epithelial apoptosis and volume reduction (20-30% over 6-12 months). They reduce progression risk and need for surgery. Reference: McConnell JD. N Engl J Med. 1998.',
'medium', 'comprehension'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Finasteride inhibits:',
'5-alpha reductase type 1 only', '5-alpha reductase type 2 only', 'Both type 1 and type 2', 'Aromatase', 'Alpha-1 adrenergic receptors',
'B', 'Finasteride selectively inhibits 5-alpha reductase type 2 (predominant in prostate). Dutasteride inhibits both types 1 and 2. Clinical difference is minimal. Both reduce serum DHT and PSA by approximately 50%. Reference: McConnell JD. N Engl J Med. 1998.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'5-alpha reductase inhibitors are most effective in men with:',
'Small prostates (<30mL)', 'Large prostates (>40mL)', 'Normal-sized prostates', 'Any prostate size equally', 'Only very young men',
'B', '5-alpha reductase inhibitors are most effective in men with larger prostates (>40mL) as there is more tissue to shrink. Benefits include reduced symptom progression, AUR, and need for surgery. Reference: McConnell JD. J Urol. 2003 (MTOPS trial).',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Side effects of 5-alpha reductase inhibitors include:',
'Postural hypotension', 'Decreased libido, erectile dysfunction, ejaculatory disorders', 'Dizziness', 'Floppy iris syndrome', 'Tachycardia',
'B', 'Sexual side effects of 5-ARIs include: decreased libido (3-5%), erectile dysfunction (5-8%), and decreased ejaculate volume. These may persist after discontinuation in some men. PSA is reduced by ~50%. Reference: McConnell JD. N Engl J Med. 1998.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'When interpreting PSA in men on 5-alpha reductase inhibitors:',
'PSA is unaffected', 'PSA should be doubled after 6 months of treatment', 'PSA increases', 'PSA becomes unreliable and should not be measured', 'PSA should be halved',
'B', '5-ARIs reduce PSA by approximately 50% after 6 months. When interpreting PSA in men on these drugs, the value should be doubled to compare with normal ranges. A rise in PSA while on 5-ARIs is concerning for cancer. Reference: D''Amico AV. J Urol. 2006.',
'hard', 'application'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Combination therapy (alpha-blocker + 5-ARI) is most beneficial for:',
'Men with small prostates', 'Men with large prostates (>40mL) and moderate-severe symptoms', 'All men with BPH', 'Men with mild symptoms only', 'Only after surgery',
'B', 'Combination therapy provides greater symptom improvement and reduces progression risk more than monotherapy, particularly in men with larger prostates (>40mL) and moderate-severe symptoms. MTOPS and CombAT trials demonstrated these benefits. Reference: McConnell JD. J Urol. 2003.',
'medium', 'application'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Phosphodiesterase-5 inhibitors (e.g., tadalafil) are used in BPH because:',
'They shrink the prostate', 'They improve LUTS and are useful in men with concurrent erectile dysfunction', 'They replace alpha-blockers', 'They are the first-line treatment', 'They cure BPH',
'B', 'Tadalafil 5mg daily is approved for LUTS/BPH and can treat both LUTS and erectile dysfunction in the same patient. It improves smooth muscle relaxation through the NO/cGMP pathway. Reference: McVary KT. J Urol. 2007.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Anticholinergics/antimuscarinics may be added to alpha-blockers when:',
'There are only voiding symptoms', 'Storage symptoms (urgency, frequency) persist despite alpha-blocker', 'Patient has high residual volume', 'First-line for all patients', 'Never combined',
'B', 'Antimuscarinics (oxybutynin, tolterodine, solifenacin) may be added when storage symptoms persist despite alpha-blocker therapy. They target detrusor overactivity. Caution with high PVR (>150mL) due to retention risk. Reference: McVary KT. J Urol. 2011.',
'hard', 'application'),

-- Surgical Treatment (46-60)
('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Absolute indications for surgical intervention in BPH include:',
'Mild symptoms only', 'Refractory retention, recurrent UTI, bladder stones, renal insufficiency, recurrent hematuria', 'Patient preference only', 'High PSA', 'Large prostate size alone',
'B', 'Absolute surgical indications: refractory urinary retention, recurrent UTI, bladder stones, renal insufficiency from BOO, recurrent gross hematuria, and large bladder diverticula. Relative: bothersome symptoms refractory to medical therapy. Reference: McVary KT. J Urol. 2011.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Transurethral resection of the prostate (TURP) is the gold standard surgical treatment for prostates up to:',
'30 mL', '80-100 mL', '150 mL', '200 mL', 'Any size',
'B', 'TURP is the gold standard for prostates 30-80mL. For very large prostates (>80-100mL), simple prostatectomy (open or minimally invasive) or laser enucleation may be preferred due to longer resection time with TURP. Reference: Gravas S. EAU Guidelines. 2020.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'TURP syndrome is caused by:',
'Bleeding', 'Absorption of hypotonic irrigation fluid causing dilutional hyponatremia', 'Infection', 'Retrograde ejaculation', 'Urethral stricture',
'B', 'TURP syndrome results from absorption of hypotonic (glycine/sorbitol) irrigation fluid through prostatic venous sinuses. Causes dilutional hyponatremia, volume overload, and glycine toxicity. Symptoms: confusion, seizures, cardiovascular collapse. Reference: Rassweiler J. Eur Urol. 2006.',
'hard', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Risk factors for TURP syndrome include all EXCEPT:',
'Large prostate', 'Prolonged resection time (>60 minutes)', 'Low irrigation fluid bag height', 'Tall irrigating fluid bag height/high pressure', 'Open venous sinuses',
'C', 'Risk factors for TURP syndrome include: large prostate, prolonged resection (>60 min), HIGH irrigation pressure/bag height, and excessive capsular perforation opening venous sinuses. LOW bag height reduces risk. Reference: Rassweiler J. Eur Urol. 2006.',
'hard', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Bipolar TURP differs from monopolar TURP in that:',
'It uses laser', 'It uses saline irrigation, eliminating TURP syndrome risk', 'It is done open', 'It cannot treat BPH', 'It requires general anesthesia always',
'B', 'Bipolar TURP uses saline (physiological) irrigation instead of glycine, virtually eliminating the risk of TURP syndrome. It also allows longer resection time. Similar efficacy to monopolar TURP. Reference: Mamoulakis C. Eur Urol. 2009.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Retrograde ejaculation after TURP occurs in approximately:',
'5% of patients', '25% of patients', '75% of patients', '100% of patients', 'Never occurs',
'C', 'Retrograde ejaculation occurs in approximately 65-80% of men after TURP due to disruption of the bladder neck mechanism. Patients should be counseled about this before surgery, especially if fertility is desired. Reference: Rassweiler J. Eur Urol. 2006.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Holmium laser enucleation of the prostate (HoLEP) is:',
'Only for small prostates', 'Size-independent and can treat any prostate volume', 'Associated with high TURP syndrome risk', 'An open procedure', 'Only experimental',
'B', 'HoLEP enucleates the adenoma (like open prostatectomy) transurethrally using holmium laser. It is size-independent and effective for very large prostates. Uses saline irrigation (no TURP syndrome). Learning curve is significant. Reference: Gilling PJ. J Urol. 2008.',
'hard', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Simple (open) prostatectomy is indicated for:',
'All BPH cases', 'Very large prostates (>80-100mL) or when concurrent bladder surgery is needed', 'Small prostates only', 'When TURP has failed', 'Never performed anymore',
'B', 'Open simple prostatectomy is indicated for very large prostates (>80-100mL) where TURP would be prolonged/risky, or when concurrent bladder pathology (stones, diverticula) requires open surgery. Can be retropubic or transvesical approach. Reference: Gravas S. EAU Guidelines. 2020.',
'medium', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Prostatic urethral lift (UroLift) is:',
'An ablative procedure', 'A minimally invasive procedure using implants to hold lateral lobes apart', 'Only for prostate cancer', 'A medical treatment', 'An open surgery',
'B', 'UroLift uses permanent implants to hold the obstructing lateral lobes of the prostate apart, opening the urethra. It preserves sexual function (low retrograde ejaculation) but is only suitable for selected patients (prostates <80mL, no large median lobe). Reference: Roehrborn CG. Can J Urol. 2017.',
'hard', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Prostate artery embolization (PAE) treats BPH by:',
'Laser ablation', 'Blocking arterial blood supply to cause prostate infarction and shrinkage', 'Surgical resection', 'Medication delivery', 'Cryotherapy',
'B', 'PAE is performed by interventional radiology. Embolic particles are delivered into prostatic arteries, causing ischemia, infarction, and subsequent prostate volume reduction. It is an emerging alternative for poor surgical candidates. Reference: Pisco JM. Eur Urol. 2016.',
'hard', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Water vapor thermal therapy (Rezūm) treats BPH by:',
'Freezing prostate tissue', 'Using steam to ablate obstructing prostate tissue', 'Mechanical compression', 'Laser enucleation', 'Radiofrequency ablation only',
'B', 'Rezūm delivers radiofrequency-generated water vapor (steam) into the transition zone, causing cell death and tissue remodeling. It is minimally invasive, preserves sexual function, and can be done in the office. Reference: McVary KT. J Urol. 2016.',
'hard', 'knowledge'),

('c0000008-0000-0000-0000-000000000008', 'a0000003-0000-0000-0000-000000000003',
'Following TURP, patients should be advised that:',
'Immediate return to full activity is possible', 'Avoid straining, heavy lifting, and sexual activity for 4-6 weeks', 'No follow-up is needed', 'Symptoms improve immediately in all cases', 'Catheter is never needed',
'B', 'Post-TURP advice: avoid straining/heavy lifting for 4-6 weeks (risk of bleeding), avoid sexual activity for 4-6 weeks, expect some hematuria for 2-4 weeks, drink plenty of fluids. Follow-up to assess symptom improvement. Reference: Gravas S. EAU Guidelines. 2020.',
'medium', 'knowledge');

SELECT 'Surgery 3 MCQ Batch 6 (BPH): 60 questions inserted' as status;
